By Rishika Sadam Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per ...

Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.

By Rishika Sadam Dec 12 (Reuters) - Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on ...

By Rishika Sadam and Kashish Tandon Dec 12 (Reuters) - Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg ...

By Deena Beasley SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in ...

By Rishika Sadam HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug ...

By Jacob Gronholt-Pedersen COPENHAGEN (Reuters) -Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been ...

By Rishika Sadam and Abhirami G BENGALURU, Dec 5 (Reuters) - Indian health-tech startup Healthify is in talks to partner with ...

(Reuters) -Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet their main goal. Shares in Novo fell more than 12% on the news ...

By Deena Beasley and Julie Steenhuysen SAN DIEGO, Dec 3 (Reuters) - Details from two large trials of Novo Nordisk's GLP-1 ...

Dec 2 (Reuters) - Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight ...

Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.